Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Diacylglycerol kinases DGK and are lipid kinases that
2020-06-29

Diacylglycerol kinases (DGK) α and ζ are lipid kinases that limit diacylglycerol (DAG)-dependent activation pathways downstream of the TCR (Merida et al., 2015). Their upregulation in tumor infiltrating lymphocytes (TIL) has been linked to generation of hyporesponsive states that contribute to immun
-
Besides chemopreventive effects against oxidative DNA damage
2020-06-29

Besides chemopreventive effects against oxidative DNA damage we evaluated the protective effects of the three Hypericum sp. and isolated compounds against alkylating DNA damage induced by MMS in HT29 cells. Human exposure to alkylating agents, from different sources, occurs in a continuous way and i
-
Introduction Cysteinyl leukotrienes CysLTs LTC LTD and
2020-06-28

Introduction Cysteinyl leukotrienes (CysLTs), LTC4, LTD4 and LTE4, are 5-lipoxygenase pathway metabolites of arachidonic STF-118804 mg and deeply involved in bronchial asthma via activation of CysLT1 receptors [1], [2]. Specific CysLT1 receptor antagonists, including pranlukast [3], [4] and montel
-
br Funding This work was supported by grants to A
2020-06-28

Funding This work was supported by grants to A.S. from the Swedish Cancer Foundation, Sweden (Grant number: CAN, 2015/637), the Swedish Medical Council, Sweden (Grant number: 2017- 01274), the Foundations at Skåne University Hospital, Sweden and to KB, SRS, NC, BCS, and SS from the Royal Physiogr
-
Steady state mRNA levels of CYP A
2020-06-28

Steady-state mRNA levels of CYP3A isoforms were not changed during liver insufficiency. Suppression of these isoforms was observed only at the protein and activity levels, suggesting a nongenomic mechanism of CYP3A isoform downregulation during liver insufficiency. Nonetheless, transcriptional activ
-
Recent data obtained with etifoxine suggest that
2020-06-28

Recent data obtained with etifoxine suggest that facilitation of GABAergic inhibition may be also associated with an indirect mechanism implying activation of the peripheral benzodiazepine receptor with a subsequent increase in neurosteroid production (Schlichter et al., 2000, Verleye et al., 2005).
-
Two nutrient sensing pathways the cAMP protein kinase A PKA
2020-06-28

Two nutrient-sensing pathways, the cAMP-protein kinase A (PKA) pathway and the target of rapamycin complex 1 (TORC1) pathway, are implicated in Msn2/4 regulation. Under non-stress conditions, Msn2 localizes in the cytoplasm and is inactivated by both PKA-dependent phosphorylation of the nuclear loca
-
br Conclusion In this review we have discussed
2020-06-28

Conclusion In this review, we have discussed how inhibition of the CK2/CDK5 signaling axis protects WM only when inhibited before ischemia, while inhibition of the CK2/AKT/GSK3β signaling axis protects WM either before or after an ischemic injury in young, aging, and old WM (Fig. 3). CK2 activati
-
In this paper we focused on Ewing sarcoma ES a
2020-06-28

In this paper, we focused on Ewing sarcoma (ES), a rapidly growing, highly malignant bone tumor developing metastases in the vast majority of patients unless multiagent chemotherapy is applied [16]. ES is the second most frequent bone tumor in childhood and adolescence, and is characterized by the p
-
Fujimoto et al pointed out that RPN knockout alleviated
2020-06-28

Fujimoto et al. pointed out that RPN2 knockout alleviated the resistance of GC CRT0044876 (MKN74 and KATO III) to docetaxel and DDP [23]. Yuan et al. demonstrated that the depletion of RPN2 resulted in the reduction in resistance of GC cells to drugs such as irinotecan, docetaxel, doxorubicin, oxal
-
For the current studies we used the selective Epac
2020-06-28

For the current studies, we used the selective Epac agonist 8CPT-AM to directly activate the proteins. We chose this pharmacological approach since it allows a direct activation of Epacs rather than using receptor agonists such as PGE2 which could introduce confounding variables. One potential conce
-
br ET Antagonist for the Future Macitentan and Atresentan
2020-06-28

ET Antagonist for the Future: Macitentan and Atresentan Macitentan is an insurmountable antagonist, resulting from structure-activity studies to improve the efficacy and tolerability of bosentan, and gained approval in the United States in 2013 for the treatment of PAH. Actelion describes the com
-
Recent studies have also uncovered additional roles
2020-06-24

Recent studies have also uncovered additional roles for E2 enzymes and E2~Ub conjugates in modulating the activity of deubiquitinating enzymes (DUBs), such as OTUB1 (Juang et al., 2012, Wiener et al., 2013, Wiener et al., 2012). Interestingly, OTUB1 has also been shown to associate and modulate the
-
The totality of evidence from randomized clinical trials
2020-06-24

The totality of evidence from randomized clinical trials supports the premise that worsening mdm2 p53 failure is a class effect of DPP-4 inhibitors. A meta-analysis by Verma et al. (54) of 100 randomized controlled clinical trials reported that the use of DPP-4 inhibitors was accompanied a signific
-
Primases are classified into two major
2020-06-24

Primases are classified into two major groups: first, the DnaG primases, found in bacteria and bacteriophages, and second, the archaeoeukaryotic primases. Remarkably, bacterial and archaeoeukaryotic primases have no structural similarity and, presumably, evolved independently (Leipe et al., 1999). T
16169 records 847/1078 page Previous Next First page 上5页 846847848849850 下5页 Last page